Literature DB >> 7886878

The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.

G B Bartley.   

Abstract

Among incident cases of GO in Olmsted County, Minnesota: GO affected females six times more frequently than males (86% versus 14% of cases, respectively). The age-adjusted incidence rate was 16 cases per 100,000 population per year for females and 2.9 cases per 100,000 population for males. The peak incidence rates were bimodal, occurring in the age groups 40 to 44 years and 60 to 64 years in females and 45 to 49 years and 65 to 69 years in males. Among patients with GO, approximately 90% had Graves' hyperthyroidism, 1% had primary hypothyroidism, 3% had Hashimoto's thyroiditis, and 5% were euthyroid. Eyelid retraction was the most common ophthalmic feature of autoimmune thyroid disease, being present either unilaterally or bilaterally in more than 90% of patients at some point in their clinical course. Exophthalmos of one or both eyes affected approximately 60% of patients, restrictive extraocular myopathy was apparent in about 40% of patients, and optic nerve dysfunction occurred in either one or both eyes in 6% of patients with autoimmune thyroid disease. Only 5% of patients had the complete constellation of classic findings: eyelid retraction, exophthalmos, optic nerve dysfunction, extraocular muscle involvement, and hyperthyroidism. Upper eyelid retraction, either unilateral or bilateral, was documented in approximately 75% of patients at the time of diagnosis of GO. Lid lag also was a frequent early sign, being present either unilaterally or bilaterally in 50% of patients at the initial examination. At the time of diagnosis of GO, the most frequent ocular symptom was pain or discomfort, which affected 30% of patients. Some degree of diplopia was noted by approximately 17% of patients, lacrimation or photophobia was present in about 15% to 20% of patients, and 7.5% of patients complained of blurred vision. Decreased vision attributable to optic neuropathy was present in less than 2% of eyes at the time of diagnosis of GO. Thyroid dermopathy and acropachy accompanied GO in approximately 4% and 1% of patients, respectively. Myasthenia gravis occurred in less than 1% of patients. Superior limbic keratoconjunctivitis was documented in less than 4% of patients. The median age at the time of diagnosis of GO was 43 years (range, 8 to 88). Among patients with hyperthyroidism, 61% developed ophthalmopathy within 1 year of the onset of thyrotoxicosis. Symptoms and signs for which statistically significant changes occurred between the initial and final examinations included lacrimation, pain or ocular discomfort, photophobia, eyelid retraction, lid lag, eyelid fullness, conjunctival injection, chemosis, and exophthalmos.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7886878      PMCID: PMC1298522     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  198 in total

1.  Association of Thyrotoxicosis and Auto-immune Thyroiditis.

Authors:  W W Buchanan; W D Alexander; J Crooks; D A Koutras; E J Wayne; J R Anderson; R B Goudie
Journal:  Br Med J       Date:  1961-03-25

Review 2.  The ophthalmopathy of Graves' disease.

Authors:  D H Char
Journal:  Med Clin North Am       Date:  1991-01       Impact factor: 5.456

3.  Prevalence and clinical associations of intraocular pressure changes in Graves' disease.

Authors:  C Allen; D Stetz; S H Roman; S Podos; P Som; T F Davies
Journal:  J Clin Endocrinol Metab       Date:  1985-07       Impact factor: 5.958

4.  Prevalence, natural history and surgical treatment of exophthalmos.

Authors:  D H Streeten; G H Anderson; G F Reed; P Woo
Journal:  Clin Endocrinol (Oxf)       Date:  1987-07       Impact factor: 3.478

5.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

6.  Stressful life events and Graves' disease.

Authors:  P J Rosch
Journal:  Lancet       Date:  1993-09-04       Impact factor: 79.321

7.  Graves' hyperthyroidism and ophthalmopathy following treatment of spontaneous hypothyroidism with levothyroxine.

Authors:  P A Easton; J R Wall
Journal:  Can Med Assoc J       Date:  1981-07-01       Impact factor: 8.262

8.  High voltage orbital radiotherapy and surgical orbital decompression in the management of Graves' ophthalmopathy.

Authors:  P Pigeon; J Orgiazzi; F Berthezene; J P Gerard; J P Haguenauer; R Mornex
Journal:  Horm Res       Date:  1987

9.  Graves's disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long acting thyroid stimulator after operation.

Authors:  S C Werner; C R Feind; M Aida
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

10.  Sources of disparity in the spectrum of diabetes mellitus at incidence and prevalence.

Authors:  L J Melton; J W Ochi; P J Palumbo; C P Chu
Journal:  Diabetes Care       Date:  1983 Sep-Oct       Impact factor: 19.112

View more
  91 in total

1.  Serum levels of soluble Fas in patients with Graves' ophthalmopathy.

Authors:  K Ohtsuka; M Hashimoto
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Graded full-thickness anterior blepharotomy for upper eyelid retraction.

Authors:  Victor M Elner; Adam S Hassan; Bartley R Frueh
Journal:  Trans Am Ophthalmol Soc       Date:  2003

3.  Histopathologic analysis of palpebral conjunctiva in thyroid-related orbitopathy (an american ophthalmological society thesis).

Authors:  Don O Kikkawa
Journal:  Trans Am Ophthalmol Soc       Date:  2010-12

4.  Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?

Authors:  Colin M Dayan; Margaret R Dayan
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

5.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

6.  Effects of prostaglandin F(2α) on adipocyte biology relevant to graves' orbitopathy.

Authors:  Mohd Shazli Draman; Fiona Grennan-Jones; Lei Zhang; Peter N Taylor; Tommy Kyaw Tun; John McDermott; Paul Moriarty; Daniel Morris; Carol Lane; Seamus Sreenan; Colin Dayan; Marian Ludgate
Journal:  Thyroid       Date:  2013-11-04       Impact factor: 6.568

7.  Orbital positron emission tomography/computed tomography (PET/CT) imaging findings in Graves ophthalmopathy.

Authors:  Leonardo García-Rojas; Gloria Adame-Ocampo; Guillermo Mendoza-Vázquez; Erick Alexánderson; José Luis Tovilla-Canales
Journal:  BMC Res Notes       Date:  2013-09-04

8.  Hyperthyroid vs hypothyroid eye disease: the same severity and activity.

Authors:  M B Kashkouli; F Pakdel; V Kiavash; I Heidari; A Heirati; S Jam
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

9.  Optical coherence tomography measurements in compressive optic neuropathy associated with dysthyroid orbitopathy.

Authors:  Kyung-Ah Park; Yoon-Duck Kim; Kyung In Woo; Changwon Kee; Jong Chul Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-12       Impact factor: 3.117

Review 10.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.